Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Medtronic
Dow
McKesson
Merck

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,150,380

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,150,380 protect, and when does it expire?

Patent 6,150,380 protects PRILOSEC and is included in one NDA.

Protection for PRILOSEC has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-one patent family members in thirty-seven countries.

Summary for Patent: 6,150,380
Title: Crystalline form of omeprazole
Abstract:The present invention relates to a novel crystalline form of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benz imidazole, known under the generic name omeprazole. Further, the present invention also relates to the use of the novel crystalline form of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benz imidazole for the treatment of gastrointestinal disorders, pharmaceutical compositions containing it as well as processes for the preparation of the novel crystalline form of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benz imidazole.
Inventor(s): Lovqvist; Karin (Molndal, SE), Sunden; Gunnel (Goteborg, SE), Noreland; David (Sodertalje, SE), Ymen; Ingvar (Saltsjo-Boo, SE)
Assignee: Astra Aktiebolag (Sodertalje, SE)
Application Number:09/202,251
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,150,380
Patent Claim Types:
see list of patent claims
Compound; Composition; Formulation; Use; Process;

Drugs Protected by US Patent 6,150,380

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astrazeneca Pharms PRILOSEC omeprazole CAPSULE, DELAYED REL PELLETS;ORAL 019810-003 Oct 5, 1995 DISCN Yes No   Start Trial   Start Trial   Start Trial
Astrazeneca Pharms PRILOSEC omeprazole CAPSULE, DELAYED REL PELLETS;ORAL 019810-001 Sep 14, 1989 DISCN Yes No   Start Trial   Start Trial   Start Trial
Astrazeneca Pharms PRILOSEC omeprazole CAPSULE, DELAYED REL PELLETS;ORAL 019810-002 Jan 15, 1998 DISCN Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,150,380

PCT Information
PCT FiledNovember 10, 1998PCT Application Number:PCT/SE98/02028
PCT Publication Date:February 25, 1999PCT Publication Number: WO99/08500

International Family Members for US Patent 6,150,380

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 016700   Start Trial
Austria 233755   Start Trial
Australia 1355199   Start Trial
Australia 756434   Start Trial
Brazil 9816067   Start Trial
Canada 2284470   Start Trial
Canada 2363810   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Boehringer Ingelheim
McKesson
Mallinckrodt
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.